Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?

Breast Cancer Research

Volumn 12, Issue SUPPL. 4, 2010, Pages

  Pritchard, Kathleen I ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CIMETIDINE; CYTOCHROME P450 2D6; DIPHENHYDRAMINE; FLUOXETINE; HALOPERIDOL; KETOCONAZOLE; METHADONE; MICONAZOLE; NICARDIPINE; PAROXETINE; QUINIDINE; QUININE; SEROTONIN ANTAGONIST; SERTRALINE; TAMOXIFEN; VENLAFAXINE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ALLELE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; DNA POLYMORPHISM; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; PHENOTYPE; BREAST TUMOR; DRUG ANTAGONISM; DRUG INTERACTION; GENETICS; METABOLISM; MORTALITY;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; TAMOXIFEN;

EID: 78650890737     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2747     Document Type: Article

References (5)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. 10.1016/S0140-6736(05)66544-0, 15894097, Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
2. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005, 23:9312-9318. 10.1200/JCO.2005.03.3266, 16361630.
3. Dezentje VO, Van Schaik R, Vletter-Bogaartz JM, Wessels JS, Hille ET, Seynaeve C, Van De Velde CJ, Nortier JW, Gelderblom H, Guchelaar H. Pharmacogenetics of tamoxifen in relation to disease-free survival in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial [abstract]. J Clin Oncol 2010, 28(suppl):abstact 510.
4. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, Paszat LF. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010, 340:c693. 2817754, 20142325, 10.1136/bmj.c693.
5. Sideras K, Ingle JN, Ames MM, Loprinzi CL, Mrazek DP, Black JL, Weinshilboum RM, Hawse JR, Spelsberg TC, Goetz M. Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol 2010, 28:2768-2776. 10.1200/JCO.2009.23.8931, 20439629.